ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2026
Long-term effectiveness and cost-effectiveness of testing for alemtuzumab antidrug antibodies to guide treatment in multiple sclerosis: a modelling study.
Timothy Jamieson et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.